Madrigal Pharma(MDGL.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Madrigal Pharma
MDGL.US
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
1.813 T
MDGL.USMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
B
BiotechnologyIndustry
Industry Ranking19/386
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-49.35%E
    • Profit Margin-27.32%E
    • Gross Margin91.38%A
  • Growth ScoreA
    • Revenue YoY256.82%A
    • Net Profit YoY20.98%B
    • Total Assets YoY23.15%A
    • Net Assets YoY-23.53%E
  • Cash ScoreB
    • Cash Flow Margin86.64%C
    • OCF YoY256.82%A
  • Operating ScoreA
    • Turnover1.02A
  • Debt ScoreC
    • Gearing Ratio55.72%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders

    Simplywall·
    US
    MDGL
    -1.99%
    US
    LABU
    -2.35%
    US
    FBT
    +0.54%
    Simplywall·
    US
    MDGL
    -1.99%
    US
    LABU
    -2.35%
    US
    FBT
    +0.54%

    Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

    Unusual Whales·
    US
    MDGL
    -1.99%
    Unusual Whales·
    US
    MDGL
    -1.99%

    Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays

    Tip Ranks·
    US
    MDGL
    -1.99%
    US
    XBI
    -0.69%
    US
    PBE
    +0.11%
    Tip Ranks·
    US
    MDGL
    -1.99%
    US
    XBI
    -0.69%
    US
    PBE
    +0.11%

    Bank of America Securities Sticks to Their Hold Rating for Madrigal Pharmaceuticals (MDGL)

    Tip Ranks·
    US
    MDGL
    -1.99%
    US
    SBIO
    -1.24%
    US
    IBB
    +0.10%
    Tip Ranks·
    US
    MDGL
    -1.99%
    US
    SBIO
    -1.24%
    US
    IBB
    +0.10%

    <![CDATA[Pharmaceutical Executive Daily: Zentalis Doses First Patient with Azenosertib in Phase III Trial]]>

    Pharmexec·
    US
    ZNTL
    -2.48%
    US
    BAYRY
    +0.27%
    US
    MDGL
    -1.99%
    Pharmexec·
    US
    ZNTL
    -2.48%
    US
    BAYRY
    +0.27%
    US
    MDGL
    -1.99%
    © 2026 Longbridge｜Disclaimer